Design, Synthesis, and Biological Evaluation of Novel Arylethanone Oxime Ether Derivatives as Potent S1PR1 Agonists for Ulcerative Colitis Therapy.
S1PR1 is a clinically validated key therapeutic target for ulcerative colitis (UC), but approved S1PR1 agonists universally suffer from the core drawback of S1PR3-mediated cardiotoxicity. Herein, we designed and synthesized multiple novel arylethanone oxime ethers-based S1PR1 agonists. Among them, compound 13d exhibite...